[{"address1": "2445 Technology Forest Boulevard", "address2": "11th Floor", "city": "The Woodlands", "state": "TX", "zip": "77381", "country": "United States", "phone": "281 863 3000", "fax": "281 863 8088", "website": "https://www.lexpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.", "fullTimeEmployees": 285, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jeffrey L. Wade J.D.", "age": 58, "title": "President & COO", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 752046, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian T. Crum", "age": 50, "title": "Senior VP, General Counsel & Secretary", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 596479, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alan J. Main Ph.D.", "age": 69, "title": "Executive Vice President of Innovation & Chemical Sciences", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 576962, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Craig B. Granowitz M.D., Ph.D.", "age": 58, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 652483, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Exton Ph.D.", "age": 53, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen L. Alexander", "age": 55, "title": "Vice President of Finance & Accounting", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dixon  Terry", "title": "Vice President of Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carrie  Siragusa", "title": "Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Desiree  Gendron", "title": "Vice President of Sales & Training", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 10, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.63, "open": 1.64, "dayLow": 1.58, "dayHigh": 1.65, "regularMarketPreviousClose": 1.63, "regularMarketOpen": 1.64, "regularMarketDayLow": 1.58, "regularMarketDayHigh": 1.65, "beta": 1.294, "forwardPE": -2.8421054, "volume": 1666600, "regularMarketVolume": 1666600, "averageVolume": 2954690, "averageVolume10days": 2837780, "averageDailyVolume10Day": 2837780, "bid": 1.61, "ask": 1.63, "bidSize": 100, "askSize": 2100, "marketCap": 585617024, "fiftyTwoWeekLow": 0.92, "fiftyTwoWeekHigh": 3.73, "priceToSalesTrailing12Months": 160.83961, "fiftyDayAverage": 1.8308, "twoHundredDayAverage": 1.8278, "currency": "USD", "enterpriseValue": 384944448, "floatShares": 182141508, "sharesOutstanding": 361492000, "sharesShort": 24533246, "sharesShortPriorMonth": 20875691, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0679, "heldPercentInsiders": 0.01148, "heldPercentInstitutions": 0.7924, "shortRatio": 7.37, "shortPercentOfFloat": 0.1505, "bookValue": 0.664, "priceToBook": 2.4397593, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -202107008, "trailingEps": -0.78, "forwardEps": -0.57, "pegRatio": -0.04, "lastSplitFactor": "1:7", "lastSplitDate": 1432166400, "enterpriseToRevenue": 105.725, "enterpriseToEbitda": -1.959, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LXRX", "underlyingSymbol": "LXRX", "shortName": "Lexicon Pharmaceuticals, Inc.", "longName": "Lexicon Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 955114200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6b83959b-e6b7-35de-9412-08dec8b7133f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.62, "targetHighPrice": 10.0, "targetLowPrice": 2.0, "targetMeanPrice": 6.2, "targetMedianPrice": 5.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 309964000, "totalCashPerShare": 0.857, "ebitda": -196474000, "totalDebt": 105676000, "quickRatio": 11.213, "currentRatio": 11.51, "totalRevenue": 3641000, "debtToEquity": 44.035, "revenuePerShare": 0.014, "returnOnAssets": -0.35694, "returnOnEquity": -0.9481, "freeCashflow": -116793752, "operatingCashflow": -195836992, "revenueGrowth": 4.196, "operatingMargins": -33.60899, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]